Cancer Treatment with Gene Therapy and Radiation Therapy

Advances in Cancer Research

Volumn 115, Issue , 2012, Pages 221-263

  Kaliberov, Sergey A ^a   Buchsbaum, Donald J ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b The University of Alabama at Birmingham   (United States)

Author keywords

DNA damage repair; Gene therapy; Molecular chemotherapy; Radiation responsive promoters; Radiation therapy

Indexed keywords

ADENOVIRUS VECTOR; ATM PROTEIN; ATR PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOSINE DEAMINASE; EARLY GROWTH RESPONSE FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUCYTOSINE; GANCICLOVIR; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; GROWTH ARREST AND DNA DAMAGE NDUCIBLE PROTEIN 45 ALPHA; HERPESVIRUS VECTOR; HISTONE H2AX; LENTIVIRUS VECTOR; LIPOSOME; OCTAMER TRANSCRIPTION FACTOR 1; PARVOVIRUS VECTOR; POLYMER; POXVIRUS VECTOR; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RECOMBINANT DNA; RETROVIRUS VECTOR; SITIMAGENE CERADENOVEC; STAT3 PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BYSTANDER EFFECT; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL CYCLE CHECKPOINT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL JUNCTION; CELL PROLIFERATION; CELL STRESS; CELL SURVIVAL; CELLULAR STRESS RESPONSE; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DNA SYNTHESIS; DRUG CYTOTOXICITY; ENDOCYTOSIS; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INTRACELLULAR SIGNALING; IONIZING RADIATION; MUTAGENESIS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIATION; RADIATION DOSE; RADIATION RESPONSE; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; SURVIVAL RATE; TRANSGENE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; CLINICAL TRIAL (TOPIC); DNA RESPONSIVE ELEMENT; GENE THERAPY; GENE TRANSFER; GENETICS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NEOPLASM; ONCOLOGY; PROMOTER REGION; RADIOTHERAPY; REVIEW;

ANIMALS; APOPTOSIS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DNA REPAIR; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PROMOTER REGIONS, GENETIC; RADIOTHERAPY; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION;

EID: 84866778834     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-398342-8.00007-0     Document Type: Chapter

References (217)

1. Adamina M., Daetwiler S., Rosenthal R., Zajac P. Clinical applications of recombinant virus-based cancer immunotherapy. Expert Opinion on Biological Therapy 2005, 5:1211-1224.
2. Aggarwal B.B., Kunnumakkara A.B., Harikumar K.B., Gupta S.R., Tharakan S.T., Koca C., et al. Signal transducer and activator of transcription-3, inflammation, and cancer: How intimate is the relationship?. Annals of the New York Academy of Sciences 2009, 1171:59-76.
3. Andreassen P.R., Ho G.P., D'Andrea A.D. DNA damage responses and their many interactions with the replication fork. Carcinogenesis 2006, 27:883-892.
4. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature Medicine 2007, 13:1050-1059.
5. Arlen P.M., Gulley J.L., Madan R.A., Hodge J.W., Schlom J. Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. Critical Reviews in Immunology 2007, 27:451-462.
6. Atkinson G., Hall S.J. Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer. Urology 1999, 54:1098-1104.
7. Azria D., Dorvillius M., Gourgou S., Martineau P., Robert B., Pugniere M., et al. Enhancement of radiation therapy by tumor necrosis factor alpha in human colon cancer using a bispecific antibody. International Journal of Radiation Oncology, Biology, Physics 2003, 55:1363-1373.
8. Bakkenist C.J., Kastan M.B. Phosphatases join kinases in DNA-damage response pathways. Trends in Cell Biology 2004, 14:339-341.
9. Barrett D.M., Black S.M., Todor H., Schmidt-Ullrich R.K., Dawson K.S., Mikkelsen R.B. Inhibition of protein-tyrosine phosphatases by mild oxidative stresses is dependent on S-nitrosylation. The Journal of Biological Chemistry 2005, 280:14453-14461.
10. Bauerschmitz G.J., Barker S.D., Hemminki A. Adenoviral gene therapy for cancer: From vectors to targeted and replication competent agents (review). International Journal of Oncology 2002, 21:1161-1174.
11. Beetz A., Peter R.U., Oppel T., Kaffenberger W., Rupec R.A., Meyer M., et al. NF-kappaB and AP-1 are responsible for inducibility of the IL-6 promoter by ionizing radiation in HeLa cells. International Journal of Radiation Biology 2000, 76:1443-1453.
12. Berthault N., Maury B., Agrario C., Herbette A., Sun J.S., Peyrieras N., et al. Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems. Cancer Gene Therapy 2011, 18:695-706.
13. Bickenbach K.A., Veerapong J., Shao M.Y., Mauceri H.J., Posner M.C., Kron S.J., et al. Resveratrol is an effective inducer of CArG-driven TNF-alpha gene therapy. Cancer Gene Therapy 2008, 15:133-139.
14. Bjornsti M.A., Houghton P.J. The TOR pathway: A target for cancer therapy. Nature Reviews. Cancer 2004, 4:335-348.
15. Blackburn R.V., Galoforo S.S., Corry P.M., Lee Y.J. Adenoviral-mediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells. Cancer Research 1998, 58:1358-1362.
16. Blalock W.L., Weinstein-Oppenheimer C., Chang F., Hoyle P.E., Wang X.Y., Algate P.A., et al. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: Possible sites for intervention with anti-neoplastic drugs. Leukemia 1999, 13:1109-1166.
17. Blundell R., Kaminski N., Harrison D. Increase in p21 expression independent of the p53 pathway in bleomycin-induced lung fibrosis. Experimental and Molecular Pathology 2004, 77:231-237.
18. Boothman D.A., Lee I.W., Sahijdak W.M. Isolation of an X-ray-responsive element in the promoter region of tissue-type plasminogen activator: Potential uses of X-ray-responsive elements for gene therapy. Radiation Research 1994, 138:S68-S71.
19. Bray D., Yu S.Z., Koprowski H., Rhee J., Kumar S., Pericle F., et al. Combination nonviral interleukin 2 gene therapy and external-beam radiation therapy for head and neck cancer. Archives of Otolaryngology-Head & Neck Surgery 2003, 129:618-622.
20. Burma S., Chen B.P., Chen D.J. Role of non-homologous end joining (NHEJ) in maintaining genomic integrity. DNA Repair 2006, 5:1042-1048.
21. Burma S., Chen B.P., Murphy M., Kurimasa A., Chen D.J. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. The Journal of Biological Chemistry 2001, 276:42462-42467.
22. Canman C.E., Lim D.S., Cimprich K.A., Taya Y., Tamai K., Sakaguchi K., et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998, 281:1677-1679.
23. Cao C., Mu Y., Hallahan D.E., Lu B. XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 2004, 23:7047-7052.
24. Chakraborty M., Abrams S.I., Coleman C.N., Camphausen K., Schlom J., Hodge J.W. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Research 2004, 64:4328-4337.
25. Chakravarty P.K., Alfieri A., Thomas E.K., Beri V., Tanaka K.E., Vikram B., et al. Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Research 1999, 59:6028-6032.
26. Chen Y., DeWeese T., Dilley J., Zhang Y., Li Y., Ramesh N., et al. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Research 2001, 61:5453-5460.
27. Chen G.G., Sin F.L., Leung B.C., Ng H.K., Poon W.S. Glioblastoma cells deficient in DNA-dependent protein kinase are resistant to cell death. Journal of Cellular Physiology 2005, 203:127-132.
28. Cheon J., Kim H.K., Moon D.G., Yoon D.K., Cho J.H., Koh S.K. Adenovirus-mediated suicide-gene therapy using the herpes simplex virus thymidine kinase gene in cell and animal models of human prostate cancer: Changes in tumour cell proliferative activity. BJU International 2000, 85:759-766.
29. Chia M.C., Shi W., Li J.H., Sanchez O., Strathdee C.A., Huang D., et al. A conditionally replicating adenovirus for nasopharyngeal carcinoma gene therapy. Molecular Therapy 2004, 9:804-817.
30. Chiang C.-S., Hong J.-H., Wu Y.C., McBride W.H., Dougherty G.J. Combining radiation therapy with interleukin-3 gene immunotherapy. Cancer Gene Therapy 2000, 7:1172-1178.
31. Chiarugi P., Cirri P. Redox regulation of protein tyrosine phosphatases during receptor tyrosine kinase signal transduction. Trends in Biochemical Sciences 2003, 28:509-514.
32. Christy B., Nathans D. Functional serum response elements upstream of the growth factor-inducible gene zif268. Molecular and Cellular Biology 1989, 9:4889-4895.
33. Cotugno G., Aurilio M., Annunziata P., Capalbo A., Faella A., Rinaldi V., et al. Noninvasive repetitive imaging of somatostatin receptor 2 gene transfer with positron emission tomography. Human Gene Therapy 2011, 22:189-196.
34. Coulter J.A., McCarthy H.O., Worthington J., Robson T., Scott S., Hirst D.G. The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation. Gene Therapy 2008, 15:495-503.
35. Criswell T., Leskov K., Miyamoto S., Luo G., Boothman D.A. Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene 2003, 22:5813-5827.
36. Daino K., Ichimura S., Nenoi M. Comprehensive search for X-ray-responsive elements and binding factors in the regulatory region of the GADD45a gene. Journal of Radiation Research (Tokyo) 2003, 44:311-318.
37. Daino K., Ichimura S., Nenoi M. Both the basal transcriptional activity of the GADD45A gene and its enhancement after ionizing irradiation are mediated by AP-1 element. Biochimica et Biophysica Acta 2006, 1759:458-469.
38. Datta R., Rubin E., Sukhatme V., Qureshi S., Hallahan D., Weichselbaum R.R., et al. Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:10149-10153.
39. Datta R., Taneja N., Sukhatme V.P., Qureshi S.A., Weichselbaum R., Kufe D.W. Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:2419-2422.
40. Davis M.A., Tang H.Y., Maybaum J., Lawrence T.S. Dependence of fluorodeoxyuridine-mediated radiosensitization on S phase progression. International Journal of Radiation Biology 1995, 67:509-517.
41. de Melo M.P., de Lima T.M., Pithon-Curi T.C., Curi R. The mechanism of indole acetic acid cytotoxicity. Toxicology Letters 2004, 148:103-111.
42. Demaria S., Bhardwaj N., McBride W.H., Formenti S.C. Combining radiotherapy and immunotherapy: A revived partnership. International Journal of Radiation Oncology, Biology, Physics 2005, 63:655-666.
43. Demaria S., Ng B., Devitt M.L., Babb J.S., Kawashima N., Liebes L., et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. International Journal of Radiation Oncology, Biology, Physics 2004, 58:862-870.
44. DeWeese T.L., van der Poel H., Li S., Mikhak B., Drew R., Goemann M., et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Research 2001, 61:7464-7472.
45. Dilber M.S., Abedi M.R., Christensson B., Bjorkstrand B., Kidder G.M., Naus C.C., et al. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Research 1997, 57:1523-1528.
46. Dritschilo A., Huang C.H., Rudin C.M., Marshall J., Collins B., Dul J.L., et al. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clinical Cancer Research 2006, 12:1251-1259.
47. Eastham J.A., Chen S.H., Sehgal I., Yang G., Timme T.L., Hall S.J., et al. Prostate cancer gene therapy: Herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Human Gene Therapy 1996, 7:515-523.
48. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825.
49. Elshami A.A., Saavedra A., Zhang H., Kucharczuk J.C., Spray D.C., Fishman G.I., et al. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Therapy 1996, 3:85-92.
50. Emdad L., Sarkar D., Lebedeva I.V., Su Z.Z., Gupta P., Mahasreshti P.J., et al. Ionizing radiation enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human ovarian cancer. Journal of Cellular Physiology 2006, 208:298-306.
51. Falck J., Coates J., Jackson S.P. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 2005, 434:605-611.
52. Fischer U., Meese E. Glioblastoma multiforme: The role of DSB repair between genotype and phenotype. Oncogene 2007, 26:7809-7815.
53. Formenti S.C. Immunological aspects of local radiotherapy: Clinical relevance. Discovery Medicine 2010, 9:119-124.
54. Fornace A.J., Alamo I., Hollander M.C. DNA damage-inducible transcripts in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America 1988, 85:8800-8804.
55. Fornace A.J., Nebert D.W., Hollander M.C., Luethy J.D., Papathanasiou M., Fargnoli J., et al. Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents. Molecular and Cellular Biology 1989, 9:4196-4203.
56. Freeman S.M., Abboud C.N., Whartenby K.A., Packman C.H., Koeplin D.S., Moolten F.L., et al. The " bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Research 1993, 53:5274-5283.
57. Freytag S.O., Khil M., Stricker H., Peabody J., Menon M., DePeralta-Venturina M., et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Research 2002, 62:4968-4976.
58. Freytag S.O., Stricker H., Peabody J., Pegg J., Paielli D., Movsas B., et al. Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Molecular Therapy 2007, 15:636-642.
59. Freytag S.O., Stricker H., Pegg J., Paielli D., Pradhan D.G., Peabody J., et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Research 2003, 63:7497-7506.
60. Galabova-Kovacs G., Kolbus A., Matzen D., Meissl K., Piazzolla D., Rubiolo C., et al. ERK and beyond: Insights from B-Raf and Raf-1 conditional knockouts. Cell Cycle 2006, 5:1514-1518.
61. Gallardo D., Drazan K.E., McBride W.H. Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Research 1996, 56:4891-4893.
62. Gatei M., Sloper K., Sorensen C., Syljuasen R., Falck J., Hobson K., et al. Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. The Journal of Biological Chemistry 2003, 278:14806-14811.
63. Geoerger B., Grill J., Opolon P., Morizet J., Aubert G., Lecluse Y., et al. Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts. British Journal of Cancer 2003, 89:577-584.
64. Gessler M., Poustka A., Cavenee W., Neve R.L., Orkin S.H., Bruns G.A. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990, 343:774-778.
65. Glover D.J., Lipps H.J., Jans D.A. Towards safe, non-viral therapeutic gene expression in humans. Nature Reviews. Genetics 2005, 6:299-310.
66. Gokhale P.C., McRae D., Monia B.P., Bagg A., Rahman A., Dritschilo A., et al. Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo. Antisense & Nucleic Acid Drug Development 1999, 9:191-201.
67. Goldkorn T., Balaban N., Shannon M., Matsukuma K. EGF receptor phosphorylation is affected by ionizing radiation. Biochimica et Biophysica Acta 1997, 1358:289-299.
68. Greco O., Powell T.M., Marples B., Joiner M.C., Scott S.D. Gene therapy vectors containing CArG elements from the Egr1 gene are activated by neutron irradiation, cisplatin and doxorubicin. Cancer Gene Therapy 2005, 12:655-662.
69. Greco O., Tozer G.M., Dachs G.U. Oxic and anoxic enhancement of radiation-mediated toxicity by horseradish peroxidase/indole-3-acetic acid gene therapy. International Journal of Radiation Biology 2002, 78:173-181.
70. Gridley D.S., Glisson W.C., Uhm J.R. Interaction of tumour necrosis factor-alpha and radiation against human colon tumour cells. Therapeutic Immunology 1994, 1:25-31.
71. Gridley D.S., Miller G.M., Luo X., Cao J.D., Timiryasova T.M., Fodor I., et al. Proton radiation and TNF-alpha/Bax gene therapy for orthotopic C6 brain tumor in Wistar rats. Technology in Cancer Research & Treatment 2004, 3:217-227.
72. Gulbins E., Kolesnick R. Raft ceramide in molecular medicine. Oncogene 2003, 22:7070-7077.
73. Hacein-Bey-Abina S., von Kalle C., Schmidt M., Le Deist F., Wulffraat N., McIntyre E., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. The New England Journal of Medicine 2003, 348:255-256.
74. Hallahan D.E., Beckett M.A., Kufe D., Weichselbaum R.R. The interaction between recombinant human tumor necrosis factor and radiation in 13 human tumor cell lines. International Journal of Radiation Oncology, Biology, Physics 1990, 19:69-74.
75. Hallahan D.E., Mauceri H.J., Seung L.P., Dunphy E.J., Wayne J.D., Hanna N.N., et al. Spatial and temporal control of gene therapy using ionizing radiation. Nature Medicine 1995, 1:786-791.
76. Hallahan D.E., Spriggs D.R., Beckett M.A., Kufe D.W. Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proceedings of the National Academy of Sciences of the United States of America 1989, 86:10104-10107.
77. Hallahan D.E., Sukhatme V.P., Sherman M.L., Virudachalam S., Kufe D., Weichselbaum R.R. Protein kinase C mediates x-ray inducibility of nuclear signal transducers EGR1 and JUN. Proceedings of the National Academy of Sciences of the United States of America 1991, 88:2156-2160.
78. Hallahan D.E., Virudachalam S., Beckett M., Sherman M.L., Kufe D., Weichselbaum R.R. Mechanisms of X-ray-mediated protooncogene c-jun expression in radiation-induced human sarcoma cell lines. International Journal of Radiation Oncology, Biology, Physics 1991, 21:1677-1681.
79. Hamdi M., Kool J., Cornelissen-Steijger P., Carlotti F., Popeijus H.E., van der Burgt C., et al. DNA damage in transcribed genes induces apoptosis via the JNK pathway and the JNK-phosphatase MKP-1. Oncogene 2005, 24:7135-7144.
80. Hamstra D.A., Rice D.J., Pu A., Oyedijo D., Ross B.D., Rehemtulla A. Combined radiation and enzyme/prodrug treatment for head and neck cancer in an orthotopic animal model. Radiation Research 1999, 152:499-507.
81. Hara T., Omura-Minamisawa M., Chao C., Nakagami Y., Ito M., Inoue T. Bcl-2 inhibitors potentiate the cytotoxic effects of radiation in Bcl-2 overexpressing radioresistant tumor cells. International Journal of Radiation Oncology, Biology, Physics 2005, 61:517-528.
82. Harari P.M., Huang S.M. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Seminars in Radiation Oncology 2001, 11:281-289.
83. Higuchi Y., Asaumi J., Murakami J., Matsuzaki H., Wakasa T., Inoue T., et al. Thermoradiotherapy combined with adenoviral p53 gene therapy in head and neck squamous cell carcinoma cell lines. Oncology Reports 2003, 10:415-420.
84. Hillman G.G., Slos P., Wang Y., Wright J.L., Layer A., De Meyer M., et al. Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma. Cancer Gene Therapy 2004, 11:61-72.
85. Hoganson D.K., Batra R.K., Olsen J.C., Boucher R.C. Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. Cancer Research 1996, 56:1315-1323.
86. Holder J.W., Elmore E., Barrett J.C. Gap junction function and cancer. Cancer Research 1993, 53:3475-3485.
87. Hsu H., Rainov N.G., Quinones A., Eling D.J., Sakamoto K.M., Spear M.A. Combined radiation and cytochrome CYP4B1/4-ipomeanol gene therapy using the EGR1 promoter. Anticancer Research 2003, 23:2723-2728.
88. Huber B.E., Austin E.A., Richards C.A., Davis S.T., Good S.S. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:8302-8306.
89. Hynes N.E., Lane H.A. ERBB receptors and cancer: The complexity of targeted inhibitors. Nature Reviews. Cancer 2005, 5:341-354.
90. Ishida A., Sasaguri T., Kosaka C., Nojima H., Ogata J. Induction of the cyclin-dependent kinase inhibitor p21(Sdi1/Cip1/Waf1) by nitric oxide-generating vasodilator in vascular smooth muscle cells. The Journal of Biological Chemistry 1997, 272:10050-10057.
91. Ishihara H., Tsuneoka K., Dimchev A.B., Shikita M. Induction of the expression of the interleukin-1 beta gene in mouse spleen by ionizing radiation. Radiation Research 1993, 133:321-326.
92. Ishizawar R., Parsons S.J. c-Src and cooperating partners in human cancer. Cancer Cell 2004, 6:209-214.
93. Iwadate Y., Yamaura A., Sakiyama S., Sato Y., Tagawa M. Glioma-specific cytotoxic T cells can be effectively induced by subcutaneous vaccination of irradiated wild-type tumor cells without artificial cytokine production. International Journal of Oncology 2003, 23:483-488.
94. Jahrsdorfer B., Weiner G.J. CpG oligodeoxynucleotides as immunotherapy in cancer. Update on Cancer Therapeutics 2008, 3:27-32.
95. Jazayeri A., Falck J., Lukas C., Bartek J., Smith G.C., Lukas J., et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nature Cell Biology 2006, 8:37-45.
96. Jia Z.Y., Deng H.F., Huang R., Yang Y.Y., Yang X.C., Qi Z.Z., et al. In vitro and in vivo studies of adenovirus-mediated human norepinephrine transporter gene transduction to hepatocellular carcinoma. Cancer Gene Therapy 2011, 18:196-205.
97. Jin S., Fan F., Fan W., Zhao H., Tong T., Blanck P., et al. Transcription factors Oct-1 and NF-YA regulate the p53-independent induction of the GADD45 following DNA damage. Oncogene 2001, 20:2683-2690.
98. Joki T., Nakamura M., Ohno T. Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir. Human Gene Therapy 1995, 6:1507-1513.
99. Kaliberov S., Buchsbaum D.J., Gillespie G.Y., Curiel D.T., Carpenter M., Arafat W.O., et al. Adenovirus-mediated transfer of Bax driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells. Molecular Therapy 2002, 6:190-198.
100. Kaliberov S.A., Kaliberova L.N., Buchsbaum D.J. Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas. Gene Therapy 2005, 12:407-417.
101. Kaliberov S.A., Kaliberova L., Stockard C.R., Grizzle W.E., Buchsbaum D.J. Adenovirus-mediated flt-1 targeted proapoptotic gene therapy of human prostate cancer. Molecular Therapy 2004, 10:1059-1070.
102. Kaliberov S.A., Markert J.M., Gillespie G.Y., Krendelchtchikova V., Della Manna D., Sellers J.C., et al. Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma. Gene Therapy 2007, 14:1111-1119.
103. Kaliberova L.N., Della Manna D.L., Krendelchtchikova V., Black M.E., Buchsbaum D.J., Kaliberov S.A. Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene. Molecular Cancer Therapeutics 2008, 7:2845-2854.
104. Kambara H., Tamiya T., Ono Y., Ohtsuka S., Terada K., Adachi Y., et al. Combined radiation and gene therapy for brain tumors with adenovirus-mediated transfer of cytosine deaminase and uracil phosphoribosyltransferase genes. Cancer Gene Therapy 2002, 9:840-845.
105. Kauffmann A., Rosselli F., Lazar V., Winnepenninckx V., Mansuet-Lupo A., Dessen P., et al. High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene 2008, 27:565-573.
106. Kavanagh B.D., Dent P., Schmidt-Ullrich R.K., Chen P., Mikkelsen R.B. Calcium-dependent stimulation of mitogen-activated protein kinase activity in A431 cells by low doses of ionizing radiation. Radiation Research 1998, 149:579-587.
107. Kavanagh B.D., Lin P.-S., Chen P., Schmidt-Ullrich R.K. Radiation-induced enhanced proliferation of human squamous cancer cells in vitro: A release from inhibition by epidermal growth factor. Clinical Cancer Research 1995, 1:1557-1562.
108. Khanna K.K., Lavin M.F. Ionizing radiation and UV induction of p53 protein by different pathways in ataxia-telangiectasia cells. Oncogene 1993, 8:3307-3312.
109. Kievit E., Nyati M.K., Ng E., Stegman L.D., Parsels J., Ross B.D., et al. Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts. Cancer Research 2000, 60:6649-6655.
110. Kim S.H., Kim J.H., Kolozsvary A., Brown S.L., Freytag S.O. Preferential radiosensitization of 9L glioma cells transduced with HSV-tk gene by acyclovir. Journal of Neuro-Oncology 1997, 33:189-194.
111. Kim J.H., Kolozsvary A., Rogulski K., Khil M.S., Brown S.L., Freytag S.O. Selective radiosensitization of 9L glioma in the brain transduced with double suicide fusion gene. The Cancer Journal from Scientific American 1998, 4:364-369.
112. Kim S.H., Wong R.J., Kooby D.A., Carew J.F., Adusumilli P.S., Patel S.G., et al. Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck. European Journal of Cancer 2005, 41:313-322.
113. Krieg A.M. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Current Oncology Reports 2004, 6:88-95.
114. Kuriyama S., Masui K., Sakamoto T., Nakatani T., Kikukawa M., Tsujinoue H., et al. Bystander effect caused by cytosine deaminase gene and 5-fluorocytosine in vitro is substantially mediated by generated 5-fluorouracil. Anticancer Research 1998, 18:3399-3406.
115. Lai S.Y., Koppikar P., Thomas S.M., Childs E.E., Egloff A.M., Seethala R.R., et al. Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: First human application and potential antitumor mechanisms. Journal of Clinical Oncology 2009, 27:1235-1242.
116. Lamfers M.L., Grill J., Dirven C.M., Van Beusechem V.W., Geoerger B., Van Den Berg J., et al. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Research 2002, 62:5736-5742.
117. Lammering G., Hewit T.H., Valerie K., Lin P.S., Contessa J.N., Schmidt-Ullrich R.K. Anti-erbB receptor strategy as a gene therapeutic intervention to improve radiotherapy in malignant human tumours. International Journal of Radiation Biology 2003, 79:561-568.
118. Lawrence T.S., Davis M.A., Loney T.L. Fluoropyrimidine-mediated radiosensitization depends on cyclin E-dependent kinase activation. Cancer Research 1996, 56:3203-3206.
119. Lawrence T.S., Tepper J.E., Blackstock A.W. Fluoropyrimidine-radiation Interactions in cells and tumors. Seminars in Radiation Oncology 1997, 7:260-266.
120. Lee J.H., Paull T.T. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 2005, 308:551-554.
121. Li G.C., He F., Shao X., Urano M., Shen L., Kim D., et al. Adenovirus-mediated heat-activated antisense Ku70 expression radiosensitizes tumor cells in vitro and in vivo. Cancer Research 2003, 63:3268-3274.
122. Li J.H., Lax S.A., Kim J., Klamut H., Liu F.F. The effects of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma. International Journal of Radiation Oncology, Biology, Physics 1999, 43:607-616.
123. Lieber M.R., Ma Y., Pannicke U., Schwarz K. Mechanism and regulation of human non-homologous DNA end-joining. Nature Reviews. Molecular Cell Biology 2003, 4:712-720.
124. Lohr F., Hu K., Haroon Z., Samulski T.V., Huang Q., Beaty J., et al. Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy. Molecular Therapy 2000, 2:195-203.
125. Lowe S.W., Bodis S., McClatchey A., Remington L., Ruley H.E., Fisher D.E., et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994, 266:807-810.
126. Lu X., Lane D.P. Differential induction of transcriptionally active p53 following UV or ionizing radiation: Defects in chromosome instability syndromes?. Cell 1993, 75:765-778.
127. Lumniczky K., Desaknai S., Mangel L., Szende B., Hamada H., Hidvegi E.J., et al. Local tumor irradiation augments the antitumor effect of cytokine-producing autologous cancer cell vaccines in a murine glioma model. Cancer Gene Therapy 2002, 9:44-52.
128. Mahan S.D., Ireton G.C., Knoeber C., Stoddard B.L., Black M.E. Random mutagenesis and selection of Escherichia coli cytosine deaminase for cancer gene therapy. Protein Engineering, Design & Selection 2004, 17:625-633.
129. Mahan S.D., Ireton G.C., Stoddard B.L., Black M.E. Alanine-scanning mutagenesis reveals a cytosine deaminase mutant with altered substrate preference. Biochemistry 2004, 43:8957-8964.
130. Marconi P., Krisky D., Oligino T., Poliani P.L., Ramakrishnan R., Goins W.F., et al. Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:11319-11320.
131. Martin M., Vozenin M.C., Gault N., Crechet F., Pfarr C.M., Lefaix J.L. Coactivation of AP-1 activity and TGF-beta1 gene expression in the stress response of normal skin cells to ionizing radiation. Oncogene 1997, 15:981-989.
132. Mason K.A., Ariga H., Neal R., Valdecanas D., Hunter N., Krieg A.M., et al. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clinical Cancer Research 2005, 11:361-369.
133. McCarthy H.O., Worthington J., Barrett E., Cosimo E., Boyd M., Mairs R.J., et al. p21(WAF1)-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy. Gene Therapy 2007, 14:246-255.
134. McGinn C.J., Lawrence T.S. Recent advances in the use of radiosensitizing nucleosides. Seminars in Radiation Oncology 2001, 11:270-280.
135. McLoughlin J.M., McCarty T.M., Cunningham C., Clark V., Senzer N., Nemunaitis J., et al. TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: Surgical experience and long-term follow-up. Annals of Surgical Oncology 2005, 12:825-830.
136. Mercatante D.R., Mohler J.L., Kole R. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. The Journal of Biological Chemistry 2002, 277:49374-49382.
137. Mesnil M., Piccoli C., Tiraby G., Willecke K., Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:1831-1835.
138. Meyer R.G., Kupper J.H., Kandolf R., Rodemann H.P. Early growth response-1 gene (Egr-1) promoter induction by ionizing radiation in U87 malignant glioma cells in vitro. European Journal of Biochemistry 2002, 269:337-346.
139. Mezhir J.J., Smith K.D., Posner M.C., Senzer N., Yamini B., Kufe D.W., et al. Ionizing radiation: A genetic switch for cancer therapy. Cancer Gene Therapy 2006, 13:1-6.
140. Miller E.M., Kinsella T.J. Radiosensitization by fluorodeoxyuridine: Effects of thymidylate synthase inhibition and cell synchronization. Cancer Research 1992, 52:1687-1694.
141. Mullen C.A., Coale M., Lowe R., Blaese R.M. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Research 1994, 54:1503-1506.
142. Munshi A., Kurland J.F., Nishikawa T., Tanaka T., Hobbs M.L., Tucker S.L., et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clinical Cancer Research 2005, 11:4912-4922.
143. Nenoi M., Daino K., Ichimura S., Takahash S., Akuta T. Low-dose radiation response of the p21WAF1/CIP1 gene promoter transduced by adeno-associated virus vector. Experimental & Molecular Medicine 2006, 38:553-564.
144. Nikitina E.Y., Gabrilovich D.I. Combination of gamma-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: Approach to treatment of advanced stage cancer. International Journal of Cancer 2001, 94:825-833.
145. Nimura Y., Kawata T., Uzawa K., Okamura J., Liu C., Saito M., et al. Silencing Ku80 using small interfering RNA enhanced radiation sensitivity in vitro and in vivo. International Journal of Oncology 2007, 30:1477-1484.
146. Nishihara E., Nagayama Y., Narimatsu M., Namba H., Watanabe M., Niwa M., et al. Treatment of thyroid carcinoma cells with four different suicide gene/prodrug combinations in vitro. Anticancer Research 1998, 18:1521-1525.
147. Nishikawa T., Ramesh R., Munshi A., Chada S., Meyn R.E. Adenovirus-mediated mda-7 (IL24) gene therapy suppresses angiogenesis and sensitizes NSCLC xenograft tumors to radiation. Molecular Therapy 2004, 9:818-828.
148. Nishitani M.A., Sakai T., Ishii K., Zhang M., Nakano Y., Nitta Y., et al. A convenient cancer vaccine therapy with in vivo transfer of interleukin 12 expression plasmid using gene gun technology after priming with irradiated carcinoma cells. Cancer Gene Therapy 2002, 9:156-163.
149. Nyati M.K., Morgan M.A., Feng F.Y., Lawrence T.S. Integration of EGFR inhibitors with radiochemotherapy. Nature Reviews. Cancer 2006, 6:876-885.
150. O'Driscoll M., Jeggo P.A. The role of double-strand break repair-Insights from human genetics. Nature Reviews. Genetics 2006, 7:45-54.
151. Oh Y.T., Chen D.W., Dougherty G.J., McBride W.H. Adenoviral interleukin-3 gene-radiation therapy for prostate cancer in mouse model. International Journal of Radiation Oncology, Biology, Physics 2004, 59:579-583.
152. Papathanasiou M.A., Kerr N.C., Robbins J.H., McBride O.W., Alamo I., Barrett S.F., et al. Induction by ionizing radiation of the gadd45 gene in cultured human cells: Lack of mediation by protein kinase C. Molecular and Cellular Biology 1991, 11:1009-1016.
153. Park J.O., Lopez C.A., Gupta V.K., Brown C.K., Mauceri H.J., Darga T.E., et al. Transcriptional control of viral gene therapy by cisplatin. The Journal of Clinical Investigation 2002, 110:403-410.
154. Pederson L.C., Buchsbaum D.J., Vickers S.M., Kancharla S.R., Mayo M.S., Curiel D.T., et al. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. Cancer Research 1997, 57:4325-4332.
155. Pellegrini L., Yu D.S., Lo T., Anand S., Lee M., Blundell T.L., et al. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 2002, 420:287-293.
156. Prasad S., Ravindran J., Aggarwal B.B. NF-kappaB and cancer: How intimate is this relationship. Molecular and Cellular Biochemistry 2010, 336:25-37.
157. Quanz M., Berthault N., Roulin C., Roy M., Herbette A., Agrario C., et al. Small-molecule drugs mimicking DNA damage: A new strategy for sensitizing tumors to radiotherapy. Clinical Cancer Research 2009, 15:1308-1316.
158. Rass K., Reichrath J. UV damage and DNA repair in malignant melanoma and nonmelanoma skin cancer. Advances in Experimental Medicine and Biology 2008, 624:162-178.
159. Ratnam K., Low J.A. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clinical Cancer Research 2007, 13:1383-1388.
160. Rimner A., Wischhusen J., Naumann U., Gleichmann M., Steinbach J.P., Weller M. Identification by suppression subtractive hybridization of p21 as a radio-inducible gene in human glioma cells. Anticancer Research 2001, 21:3505-3508.
161. Rodriguez R., Schuur E.R., Lim H.Y., Henderson G.A., Simons J.W., Henderson D.R. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Research 1997, 57:2559-2563.
162. Rogers B.E., Zinn K.R., Lin C.-Y., Chaudhuri T.R., Buchsbaum D.J. Targeted radiotherapy with [90Y]-SMT 487 in mice bearing human nonsmall cell lung tumor xenografts induced to express human somatostatin receptor subtype 2 with an adenoviral vector. Cancer 2002, 94:1298-1305.
163. Rogulski K.R., Freytag S.O., Zhang K., Gilbert J.D., Paielli D.L., Kim J.H., et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Research 2000, 60:1193-1196.
164. Sartor C.I. Biological modifiers as potential radiosensitizers: Targeting the epidermal growth factor receptor family. Seminars in Oncology 2000, 27:15-20. discussion 92-100.
165. Sasaki Y., Morimoto I., Ishida S., Yamashita T., Imai K., Tokino T. Adenovirus-mediated transfer of the p53 family genes, p73 and p51/p63 induces cell cycle arrest and apoptosis in colorectal cancer cell lines: Potential application to gene therapy of colorectal cancer. Gene Therapy 2001, 8:1401-1408.
166. Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 2004, 306:1506-1507.
167. Schlessinger J., Lemmon M.A. Nuclear signaling by receptor tyrosine kinases: The first robin of spring. Cell 2006, 127:45-48.
168. Scott S.D., Joiner M.C., Marples B. Optimizing radiation-responsive gene promoters for radiogenetic cancer therapy. Gene Therapy 2002, 9:1396-1402.
169. Searle P.F., Chen M.J., Hu L., Race P.R., Lovering A.L., Grove J.I., et al. Nitroreductase: A prodrug-activating enzyme for cancer gene therapy. Clinical and Experimental Pharmacology & Physiology 2004, 31:811-816.
170. Senzer N., Mani S., Rosemurgy A., Nemunaitis J., Cunningham C., Guha C., et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: A phase I study in patients with solid tumors. Journal of Clinical Oncology 2004, 22:592-601.
171. Shariat S.F., Desai S., Song W., Khan T., Zhao J., Nguyen C., et al. Adenovirus-mediated transfer of inducible caspases: A novel " death switch" gene therapeutic approach to prostate cancer. Cancer Research 2001, 61:2562-2571.
172. Sherman M.L., Datta R., Hallahan D.E., Weichselbaum R.R., Kufe D.W. Ionizing radiation regulates expression of the c-jun protooncogene. Proceedings of the National Academy of Sciences of the United States of America 1990, 87:5663-5666.
173. Shi W., Teschendorf C., Muzyczka N., Siemann D.W. Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiotherapy and Oncology 2003, 66:1-9.
174. Shimura T. Acquired radioresistance of cancer and the AKT/GSK3beta/cyclin D1 overexpression cycle. Journal of Radiation Research (Tokyo) 2011, 52:539-544.
175. Shinoura N., Yamamoto N., Asai A., Kirino T., Hamada H. Adenovirus-mediated transfer of Fas ligand gene augments radiation-induced apoptosis in U-373MG glioma cells. Japanese Journal of Cancer Research 2000, 91:1044-1050.
176. Sourvinos G., Spandidos D.A. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors. Biochemical and Biophysical Research Communications 1998, 245:75-80.
177. Spitz F.R., Nguyen D., Skibber J.M., Meyn R.E., Cristiano R.J., Roth J.A. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clinical Cancer Research 1996, 2:1665-1671.
178. Spitzweg C., Baker C.H., Bergert E.R., O'Connor M.K., Morris J.C. Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression. Human Gene Therapy 2007, 18:916-924.
179. Stackhouse M.A., Buchsbaum D.J., Kancharla S.R., Grizzle W.E., Grimes C., Laffoon K., et al. Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectors. Cancer Gene Therapy 1999, 6:209-219.
180. Stackhouse M.A., Pederson L.C., Grizzle W.E., Curiel D.T., Gebert J., Haack K., et al. Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models. Gene Therapy 2000, 7:1019-1026.
181. Steinman R.A., Hoffman B., Iro A., Guillouf C., Liebermann D.A., el-Houseini M.E. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene 1994, 9:3389-3396.
182. Su Z.Z., Lebedeva I.V., Sarkar D., Emdad L., Gupta P., Kitada S., et al. Ionizing radiation enhances therapeutic activity of mda-7/IL-24: Overcoming radiation- and mda-7/IL-24-resistance in prostate cancer cells overexpressing the antiapoptotic proteins bcl-xL or bcl-2. Oncogene 2006, 25:2339-2348.
183. Takahashi S., Saito S., Ohtani N., Sakai T. Involvement of the Oct-1 regulatory element of the gadd45 promoter in the p53-independent response to ultraviolet irradiation. Cancer Research 2001, 61:1187-1195.
184. Teh B.S., Aguilar-Cordova E., Kernen K., Chou C.C., Shalev M., Vlachaki M.T., et al. Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer-A preliminary report. International Journal of Radiation Oncology, Biology, Physics 2001, 51:605-613.
185. Teitz-Tennenbaum S., Li Q., Rynkiewicz S., Ito F., Davis M.A., McGinn C.J., et al. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Research 2003, 63:8466-8475.
186. Tetzlaff M.T., Teh B.S., Timme T.L., Fujita T., Satoh T., Tabata K., et al. Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancer. Technology in Cancer Research & Treatment 2006, 5:23-36.
187. Toth K., Tarakanova V., Doronin K., Ward P., Kuppuswamy M., Locke J.E., et al. Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein. Cancer Gene Therapy 2003, 10:193-200.
188. Treisman R. The SRE: A growth factor responsive transcriptional regulator. Seminars in Cancer Biology 1990, 1:47-58.
189. Trinh Q.T., Austin E.A., Murray D.M., Knick V.C., Huber B.E. Enzyme/prodrug gene therapy: Comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Research 1995, 55:4808-4812.
190. Trofimova I., Dimtchev A., Jung M., Rosenthal D., Smulson M., Dritschilo A., et al. Gene therapy for prostate cancer by targeting poly(ADP-ribose) polymerase. Cancer Research 2002, 62:6879-6883.
191. Trujillo M.A., Oneal M.J., McDonough S., Qin R., Morris J.C. A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer. Gene Therapy 2010, 17:1325-1332.
192. Tsai-Morris C.H., Cao X.M., Sukhatme V.P. 5' flanking sequence and genomic structure of Egr-1, a murine mitogen inducible zinc finger encoding gene. Nucleic Acids Research 1988, 16:8835-8846.
193. Uchida H., Shinoura N., Kitayama J., Watanabe T., Nagawa H., Hamada H. 5-Fluorouracil efficiently enhanced apoptosis induced by adenovirus-mediated transfer of caspase-8 in DLD-1 colon cancer cells. The Journal of Gene Medicine 2003, 5:287-299.
194. Vernole P., Muzi A., Volpi A., Dorio A.S., Terrinoni A., Shah G.M., et al. Inhibition of homologous recombination by treatment with BVDU (brivudin) or by RAD51 silencing increases chromosomal damage induced by bleomycin in mismatch repair-deficient tumour cells. Mutation Research 2009, 664:39-47.
195. Wakasa T., Inoue T., Kawai N., Murakami J., Kishi K., Fukui K. The combination of ionizing radiation and expression of a wild type p53 gene via recombinant adenovirus induced a prominent tumour suppressing effect in human oral squamous cell carcinoma. The British Journal of Radiology 2002, 75:657-662.
196. Walker J.R., McGeagh K.G., Sundaresan P., Jorgensen T.J., Rabkin S.D., Martuza R.L. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Human Gene Therapy 1999, 10:2237-2243.
197. Weichselbaum R.R., Hallahan D.E., Beckett M.A., Mauceri H.J., Lee H., Sukhatme V.P., et al. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Research 1994, 54:4266-4269.
198. Weichselbaum R.R., Kufe D. Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers. Cancer Gene Therapy 2009, 16:609-619.
199. Weichselbaum R.R., Kufe D.W., Hellman S., Rasmussen H.S., King C.R., Fischer P.H., et al. Radiation-induced tumour necrosis factor-alpha expression: Clinical application of transcriptional and physical targeting of gene therapy. The Lancet Oncology 2002, 3:665-671.
200. White C.L., Menghistu T., Twigger K.R., Searle P.F., Bhide S.A., Vile R.G., et al. Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo. Gene Therapy 2008, 15:424-433.
201. Winter R.N., Rhee J.G., Kyprianou N. Caspase-1 enhances the apoptotic response of prostate cancer cells to ionizing radiation. Anticancer Research 2004, 24:1377-1386.
202. Worthington J., McCarthy H.O., Barrett E., Adams C., Robson T., Hirst D.G. Use of the radiation-inducible WAF1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment. The Journal of Gene Medicine 2004, 6:673-680.
203. Xiang D.B., Chen Z.T., Wang D., Li M.X., Xie J.Y., Zhang Y.S., et al. Chimeric adenoviral vector Ad5/F35-mediated APE1 siRNA enhances sensitivity of human colorectal cancer cells to radiotherapy in vitro and in vivo. Cancer Gene Therapy 2008, 15:625-635.
204. Xu Y., Liu Z., Kong H., Sun W., Liao Z., Zhou F., et al. Co-expression of interleukin 12 enhances antitumor effects of a novel chimeric promoter-mediated suicide gene therapy in an immunocompetent mouse model. Biochemical and Biophysical Research Communications 2011, 412:763-768.
205. Xu L., Pirollo K.F., Tang W.-H., Rait A., Chang E.H. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck xenografts. Human Gene Therapy 1999, 10:2941-2952.
206. Yacoub A., Hamed H., Emdad L., Dos Santos W., Gupta P., Broaddus W.C., et al. MDA-7/IL-24 plus radiation enhance survival in animals with intracranial primary human GBM tumors. Cancer Biology & Therapy 2008, 7:917-933.
207. Yanamandra N., Kondraganti S., Srinivasula S.M., Gujrati M., Olivero W.C., Dinh D.H., et al. Activation of caspase-9 with irradiation inhibits invasion and angiogenesis in SNB19 human glioma cells. Oncogene 2004, 23:2339-2346.
208. Yang Y.J., Chen D.Z., Li L.X., Sheng Q.S., Jin Z.K., Zhao D.F. Targeted IL-24 gene therapy inhibits cancer recurrence after liver tumor resection by inducing tumor cell apoptosis in nude mice. Hepatobiliary & Pancreatic Diseases International 2009, 8:174-178.
209. Yang D.C., Elliott R.L., Head J.F. Gene targets of antisense therapies in breast cancer. Expert Opinion on Therapeutic Targets 2002, 6:375-385.
210. Yang Y., Liu S.Z., Fu S.B. Anti-tumor effects of pNEgr-mIL-12 recombinant plasmid induced by X-irradiation and its mechanisms. Biomedical and Environmental Sciences 2004, 17:135-143.
211. Yu H., Jove R. The STATs of cancer-New molecular targets come of age. Nature Reviews. Cancer 2004, 4:97-105.
212. Yu D., Sekine E., Fujimori A., Ochiya T., Okayasu R. Down regulation of BRCA2 causes radio-sensitization of human tumor cells in vitro and in vivo. Cancer Science 2008, 99:810-815.
213. Yuan S., Qiao T., Chen W. CpG oligodeoxynucleotide 1826 enhances the Lewis lung cancer response to radiotherapy in murine tumor. Cancer Biotherapy & Radiopharmaceuticals 2011, 26:203-208.
214. Zaiss A.K., Liu Q., Bowen G.P., Wong N.C., Bartlett J.S., Muruve D.A. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. Journal of Virology 2002, 76:4580-4590.
215. Zhou B.B., Bartek J. Targeting the checkpoint kinases: Chemosensitization versus chemoprotection. Nature Reviews. Cancer 2004, 4:216-225.
216. Zhou B.B., Chaturvedi P., Spring K., Scott S.P., Johanson R.A., Mishra R., et al. Caffeine abolishes the mammalian G(2)/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity. The Journal of Biological Chemistry 2000, 275:10342-10348.
217. Zimmerman R.J., Marafino B.J., Chan A., Landre P., Winkelhake J.L. The role of oxidant injury in tumor cell sensitivity to recombinant human tumor necrosis factor in vivo. Implications for mechanisms of action. Journal of Immunology 1989, 142:1405-1409.